Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $6.61, $1.11 better than the analyst estimate of $5.50. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.04 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2024 EPS of $19.50-$20.60, versus the consensus of $19.59. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.04 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• First Carolina Financial Services CFO to retire in January 2027
• InMed Pharmaceuticals gets Nasdaq equity deficiency notice